BE2013C034I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C034I2
BE2013C034I2 BE2013C034C BE2013C034C BE2013C034I2 BE 2013C034 I2 BE2013C034 I2 BE 2013C034I2 BE 2013C034 C BE2013C034 C BE 2013C034C BE 2013C034 C BE2013C034 C BE 2013C034C BE 2013C034 I2 BE2013C034 I2 BE 2013C034I2
Authority
BE
Belgium
Application number
BE2013C034C
Other languages
Dutch (nl)
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35460826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C034(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of BE2013C034I2 publication Critical patent/BE2013C034I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BE2013C034C 2003-12-11 2013-06-07 BE2013C034I2 (en:Method)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52876003P 2003-12-11 2003-12-11
US52859203P 2003-12-11 2003-12-11
US52859303P 2003-12-11 2003-12-11
US56089404P 2004-04-09 2004-04-09
US11/010,828 US8007826B2 (en) 2003-12-11 2004-12-13 Sustained release aminopyridine composition

Publications (1)

Publication Number Publication Date
BE2013C034I2 true BE2013C034I2 (en:Method) 2024-08-08

Family

ID=35460826

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C034C BE2013C034I2 (en:Method) 2003-12-11 2013-06-07

Country Status (2)

Country Link
US (46) US8007826B2 (en:Method)
BE (1) BE2013C034I2 (en:Method)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
JP2009507047A (ja) * 2005-09-09 2009-02-19 ラボファーム インコーポレイテッド 持続性薬物放出組成物
DE102007054702B4 (de) * 2007-11-14 2018-10-18 Smartpolymer Gmbh Verfahren zur Herstellung von cellulosischen Formkörpern, cellulosischer Formkörper und dessen Verwendung
BRPI1000031A2 (pt) * 2009-02-11 2018-02-14 Acorda Therapeutics Inc métodos para tratar de modo durável a esclerose múltipla em um paciente, para tratar eficazmente a esclerose múltipla em um paciente em um período de tempo crônico, para aumentar a capacidade de caminhar e para tratar os sintomas de esclerose múltipla, e, composição
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
AR078323A1 (es) * 2009-09-04 2011-11-02 Acorda Therapeutics Inc Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple
WO2011102506A1 (ja) * 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
EP2540317A4 (en) * 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
JP5749247B2 (ja) 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
ES2703255T3 (es) 2010-10-22 2019-03-07 Univ Duke Formulaciones de liberación lenta de 5-hidroxitriptófano como un complemento para terapias pro-serotoninérgicas
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US20130030025A1 (en) 2011-01-28 2013-01-31 Wessel Thomas C Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
EA201491522A1 (ru) 2012-02-13 2014-12-30 Акорда Терапьютикс, Инк. Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
WO2014028387A1 (en) 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
BR112015004190A2 (pt) 2012-09-03 2017-07-04 Daiichi Sankyo Co Ltd composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada
WO2014093475A1 (en) 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Methods for treating parkinson's disease using aminopyridines
SG10201707543PA (en) 2013-03-14 2017-11-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US9993429B2 (en) 2013-03-15 2018-06-12 University Of Rochester Composition and methods for the treatment of peripheral nerve injury
JP2016517856A (ja) 2013-04-15 2016-06-20 アコルダ セラピュティクス，インコーポレイテッド アミノピリジンを使用した、ある種の卒中に関連した感覚運動障害を治療するための方法
DK3253377T3 (da) 2015-02-08 2021-07-12 Alkermes Pharma Ireland Ltd Monomethylfumarat-prodrug-sammensætninger
US10411512B2 (en) * 2015-04-10 2019-09-10 Qualcomm Incorporated Methods and apparatus for implementing presence and usage pattern detection in wireless charging applications
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2018186866A1 (en) 2017-04-06 2018-10-11 Cobb Joseph E Jr Sustained release compositions of 4-aminopyridine
EP3355865B8 (en) 2015-09-29 2025-02-19 Merz Pharmaceuticals, LLC Sustained release compositions of 4-aminopyridine
CN106551914A (zh) * 2015-09-29 2017-04-05 深圳翰宇药业股份有限公司 一种达方吡啶缓释片及其制备方法
US10888552B2 (en) 2016-08-12 2021-01-12 Steven Rothman Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
CH415963A (de) 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4386095A (en) 1982-02-22 1983-05-31 Cornell Research Foundation, Inc. Diaminopyridines to improve cognition
IE53703B1 (en) 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
IE54286B1 (en) 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
IE56459B1 (en) 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4562196A (en) 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4812447A (en) 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4760092A (en) 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
FI895821A7 (fi) 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
TW200462B (en:Method) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
CA2085785C (en) 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
US6284473B1 (en) 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
GB2356585B (en) * 1996-11-13 2001-07-11 Phoqus Ltd Method and apparatus for the coating of substrates for pharmaceutical use and intermediate products for use in producing solid dosage forms
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6288026B1 (en) 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
CA2534711A1 (en) 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP1888056A4 (en) 2005-06-01 2008-09-03 Teva Pharma USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
EP1940285B1 (en) 2005-09-23 2019-05-29 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
WO2008033284A2 (en) * 2006-09-11 2008-03-20 Magiq Technologies, Inc. Qkd using high-altitude platforms
EP2343976A4 (en) 2008-09-10 2011-12-14 Acorda Therapeutics Inc METHOD FOR USING AMINO-PYRIDINE COMPOSITIONS WITH DELAYED RELEASE
WO2010090730A1 (en) 2009-02-03 2010-08-12 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
BRPI1000031A2 (pt) 2009-02-11 2018-02-14 Acorda Therapeutics Inc métodos para tratar de modo durável a esclerose múltipla em um paciente, para tratar eficazmente a esclerose múltipla em um paciente em um período de tempo crônico, para aumentar a capacidade de caminhar e para tratar os sintomas de esclerose múltipla, e, composição
TWM368960U (en) * 2009-06-26 2009-11-11 Jin-Chang Guo Cable winder structure
JO3348B1 (ar) 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
AR078323A1 (es) 2009-09-04 2011-11-02 Acorda Therapeutics Inc Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple

Also Published As

Publication number Publication date
US20190022076A1 (en) 2019-01-24
US20160324840A1 (en) 2016-11-10
US20160175294A1 (en) 2016-06-23
US20220040161A1 (en) 2022-02-10
US20220296577A1 (en) 2022-09-22
US20220265624A1 (en) 2022-08-25
US20130045276A1 (en) 2013-02-21
US20050276851A1 (en) 2005-12-15
US20230293505A1 (en) 2023-09-21
US20120041034A1 (en) 2012-02-16
US20230390261A1 (en) 2023-12-07
US20190231763A1 (en) 2019-08-01
US20200368217A1 (en) 2020-11-26
US20230133230A1 (en) 2023-05-04
US20160081992A1 (en) 2016-03-24
US20130310426A1 (en) 2013-11-21
US20190134015A1 (en) 2019-05-09
US20200338053A1 (en) 2020-10-29
US20170209421A1 (en) 2017-07-27
US20210059996A1 (en) 2021-03-04
US20220142999A1 (en) 2022-05-12
US20180256555A1 (en) 2018-09-13
US20180153869A1 (en) 2018-06-07
US20100272796A1 (en) 2010-10-28
US20200230122A1 (en) 2020-07-23
US20170258730A1 (en) 2017-09-14
US20100324100A1 (en) 2010-12-23
US11786514B2 (en) 2023-10-17
US20170027874A1 (en) 2017-02-02
US20100272795A1 (en) 2010-10-28
US20100324099A1 (en) 2010-12-23
US20240156794A1 (en) 2024-05-16
US20190240206A1 (en) 2019-08-08
US8663685B2 (en) 2014-03-04
US20180125790A1 (en) 2018-05-10
US9918973B2 (en) 2018-03-20
US20100272807A1 (en) 2010-10-28
US20210308112A1 (en) 2021-10-07
US20180055774A1 (en) 2018-03-01
US20100324098A1 (en) 2010-12-23
US8007826B2 (en) 2011-08-30
US20140018397A1 (en) 2014-01-16
US20200093809A1 (en) 2020-03-26
US20170165245A1 (en) 2017-06-15
US20190381020A1 (en) 2019-12-19
US20220401426A1 (en) 2022-12-22
US20220016094A1 (en) 2022-01-20
US20240058313A1 (en) 2024-02-22
US20210205282A1 (en) 2021-07-08
US20180369216A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
BE2013C075I2 (en:Method)
BE2013C069I2 (en:Method)
BE2013C067I2 (en:Method)
BE2013C038I2 (en:Method)
BE2013C036I2 (en:Method)
BE2011C030I2 (en:Method)
BE2013C034I2 (en:Method)
IN234086B (en:Method)
JP2004074402A5 (en:Method)
BE2012C053I2 (en:Method)
JP2004160186A5 (en:Method)
JP2004093107A5 (en:Method)
JP2004223168A5 (en:Method)
JP2004166217A5 (en:Method)
JP2004221285A5 (en:Method)
JP2003263271A5 (en:Method)
JP2003348552A5 (en:Method)
AU2002339901A1 (en:Method)
AU2002316511A1 (en:Method)
AU2002327736A1 (en:Method)
AU2002324323A1 (en:Method)
AU2002329412A1 (en:Method)
AU2002321535A1 (en:Method)
AU2002331433A1 (en:Method)
AU2002253451A1 (en:Method)